Research programme: glial excitotoxin release inhibitors - QuestcorAlternative Names: GERI compounds - Questcor; Glial excitotoxin release inhibitors research programme - Questcor
Latest Information Update: 17 Oct 2005
At a glance
- Originator Questcor Pharmaceuticals
- Mechanism of Action Glial excitotoxin release inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cerebral ischaemia; Stroke
Most Recent Events
- 13 Oct 2005 Discontinued - Preclinical for Stroke in USA (unspecified route)
- 13 Oct 2005 Discontinued - Preclinical for Cerebral ischaemia in USA (unspecified route)
- 05 Mar 2002 Preclinical trials in Cerebral ischaemia in USA